Dariohealth expands glp-1 solution with prescribing capabilities through collaboration with mediorbis, targeting employers and direct-to-consumer markets

New collaboration enhances dario's comprehensive glp-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels new york , jan. 14, 2025 /prnewswire/ -- january 14, 2025 -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, today announced a collaboration with mediorbis, a multi-specialty digital health provider, to add prescribing capabilities to dario's glp-1 behavior change solution for a comprehensive medical weight loss program. this strategic addition creates a fully integrated solution for employers covering weight-loss medications and supports direct-to-consumer offerings, expanding dario's addressable market in one of the fastest-growing segments of digital health.
DRIO Ratings Summary
DRIO Quant Ranking